The Breakthrough Therapy designation is supported by data from the randomized, double-blind phase 3 HERCULES trial.

Findings seen among children and adolescents with type 1 diabetes and nonoptimal control with traditional treatment ...

The sBLA submission included results from the randomized, parallel-arm, placebo-controlled and active-controlled trial foresiGHt.

Number of people with at least one episode of HSV-attributable genital ulcer disease was 187.9 and 16.7 million for HSV-2, HSV-1 in 2020 ...

(HealthDay News) — Adults receiving chiropractic spinal manipulative therapy (SMT) for tension-type headache have a significantly lower likelihood of butalbital prescription, according to a study ...

A higher risk of liver transplant and death was observed in Ocaliva-treated patients vs those who received placebo.

The burden of respiratory syncytial virus (RSV) in young children continues to be high in the United States, according to a study published online Dec. 9 in JAMA Pediatrics. Heidi L. Moline, MD, MPH, ...

The health system defended itself by claiming it had done nothing wrong, and that Dr T had a clear duty to inform it of the ...

Interim data from a phase 3 study evaluating tecovirimat for the treatment of human mpox virus showed the antiviral did not improve time to lesion resolution compared with placebo.

Adults with asthma with cost-related medication nonadherence more likely to have asthma attacks, ED visits for asthma ...

A Prescription Drug User Fee Act target date of July 24, 2025 has been set for the sNDA application. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) ...

SER-155 is an oral, 16-strain microbiome therapeutic that works by decolonizing gastrointestinal pathogens, strengthening the epithelial barrier, and inducing immune tolerance.